News
November 2009
Presentation 2009 Annual Meeting of the Society of Integrative Oncology (SIO),
Dr. Robert A. Newman, M. D. Anderson Cancer Center
The Scientific Program Committee of the Society of Integrative Oncology (SIO) extended an invitation for an oral presentation by Dr. Robert Newman to the attendees of their annual meeting as the Best of SIO. The meeting was held on November 12-13, 2009 in New York, New York at the New York Academy of Medicine. Dr. Newman presented on Nerium oleander extract (oleandrin), titled “Development and Evaluation of a Cardiac Glycoside Extract (PBI-05204) as a Novel Anticancer Agent”.
SIO Presentation
October 2009
Patent application filed for new Nerium oleander-based extraction process to US Patent and Trademark Office and PCT Patent Office (International).
On October 13, 2009, Nerium Biotechnology, Inc. filed the new Nerium oleander-based extraction process to the US Patent and Trademark Office and PCT Patent Office (International). This extraction process incorporates pure liquid Aloe Vera to extract the unique Nerium oleander plant components in a way that preserves the unique and beneficial properties of both plants, without any additional solvents. This natural extraction process combines the unique beneficial properties of the Nerium Extract and the known beneficial properties of Aloe Vera. Nerium, if successful with this patent, will have an additional patented process for Nerium oleander extraction and its cytotoxic component oleandrin.
August 2009
Publication, Oleandrin-mediated Inhibition of Human Tumor Cell Proliferation: Importance of Na, K-ATPase Subunits as Drug Targets, published, Molecular Cancer Therapeutics
Yang, P.; Newman, R. A., et al., Oleandrin-mediated Inhibition of Human Tumor Cell Proliferation: Importance of Na, K-ATPase a Subunits as Drug Targets, Molecular Cancer Therapeutics, August 1, 2009 8, 2319 Article featured on publication cover.
Read the Publication
June 2009
Market Research initiated with University of California at Berkeley, Marketing Department.
Market research has been initiated at the University of California at Berkeley. The Berkeley Marketing Department through its International Diploma Program is conducting market research on behalf of Nerium. International students in this marketing program are currently conducting and compiling marketing research on Nerium’s dermal products (market size, competition, product positioning, product name, purchase intention, product promotion, consumer behavior, etc.). We await final report for our review and consideration in the future marketing plans of our dermal products.
May 2009
Presentation Annual Meeting of the American Society of Clinical Oncology (ASCO)
Phoenix Biotechnology, Inc. was invited to present at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. Attendees included 30,000 physicians, healthcare professionals and companies from 120 plus countries. At this meeting several hundred scientists and healthcare companies are allowed a poster presentation for discussion, although precious few are allowed to actually present to attendees. Phoenix’s presentation on May 29, 2009 to attendees was on Nerium oleander extract (oleandrin), titled PBI-05204, an inhibitor of Akt, FGF-2, NF-kb and p70S6K.
Presentation
Poster
April 2009
Product development, formulation and validation method signed with PharmaForm, LLC
Nerium has contracted with PharmaForm, LLC, in Austin, Texas. PharmaForm is the same company Phoenix Biotechnology, Inc. contracted with for product development, formulation and validation method of their product PBI-05402. This Phoenix formulation is currently in FDA Trials at the M.D. Anderson Cancer Center, in Houston, Texas.
PharmaForm is assisting Nerium in developing the validation method for its new dermal formulations and the new sublingual administration formulation of Anvirzel. PharmaForm will assist with the further development of a new administration route for Nerium extracts (pill, capsule, etc.) and is also performing product stabilization studies on the dermal and sublingual formulations.
January 2009
Pilot study initiated with Nerium oleander-based dermal cream formulation.
An additional pilot study has been initiated with Science, Toxicology & Technology (STT) on Nerium’s dermal formulation for cold sores (Herpes Virus, HSV-1). The enhanced cold sore formulation for this study will include additional antiviral compounds in the formulation.
December 2008
Sponsored Research Agreement signed with Louisiana State University (LSU)
In December 2008 Nerium signed a sponsored research agreement with Louisiana State University (LSU). The focus of this antiviral research is the Herpes Virus, HSV-1. This research will provide data for future antiviral FDA Trials.
November 2008
Public Market Approval, Ontario Securities Exchange
Nerium was granted approval by the Ontario Securities Exchange on November 26, 2008. The approval process was very extensive and demanding due to the current economic conditions; the downturn was at its peak during this application period. Nerium was very fortunate to have accomplished this goal. The next step is to move to a listing with the Canadian, Toronto Stock Exchange or the USA, Nasdaq Exchange. The listing application is currently being held pending the appropriate time and dependent upon stabilization of capital markets.
October 2008
Provisional patent application submitted for new oleander-based extraction process.
In July 2008, Science Toxicology and Technology, LLC (ST&T) provided a patentability opinion on a new method of extracting materials from oleander for medicinal use. The conclusion, after the review of the references cited, was that in their opinion the new extraction process used to extract glycosides and other compounds from Nerium-derived plant material is novel and unobvious. Nerium has provided a description of the invention and ST&T has moved forward with the Plant Extraction Method and Compositions paperwork and filed a provisional patent October 14, 2008. Nerium, if successful with this patent, will have an additional patented process for an oleander extraction and its cytotoxic component oleandrin.
August 2008
Two additional pilot studies initiated with Nerium oleander-based dermal cream formulations.
As of August 2008, two additional pilot studies have been initiated. In these studies the cream is applied to a larger surface area on each patient. One study relates to sunburn and the other to acne. In addition we are testing the Nerium dermal creams against well-known products already in the market place.
July 2008
Sponsored Research Agreement signed with M.D. Anderson Cancer Center
In July 2008 Nerium signed its own Sponsored Research Agreement directly with M. D. Anderson Cancer Center. The anti-viral research focus has been on a specific target and preliminary research has been very promising, although Nerium is unable to share details at this time. Upon completion, the next step will be the animal model testing and then human clinical trials.
July 2008
Pilot studies are initiated with Science Toxicology and Technology, LLC (Nerium oleander-based dermal cream)
After development of a basic Nerium oleander-based cream, Nerium has initiated animal and human pilot studies during the month of July 2008 with Science Toxicology and Technology, LLC. The initial human pilot is on age/liver spots and actinic keratosis. Nerium’s focus remains safety and efficacy with this new dermal application.
April 2008
Testing agreement for oleander-based dermal products signed with Science Toxicology and Technology, LLC.
In April 2008 Nerium Biotechnology, Inc. signed a research and testing agreement (the first in a series) with Science Toxicology and Technology, LLC (ST&T). Nerium discussions with ST&T provided for a model to bring our dermal formulations to market. Initial product targets would be cosmetic (Neutraceutical) versus a drug. This initial research includes an animal model to confirm safety and a series of human studies on various skin diseases, skin cancer and sun-damaged skin. The agreement also provides for initial patent research and processing for our new oleander extraction process.
April 2008
Formulation and manufacturing agreement for oleander-based dermal products signed with Affiliated Consultants International Incorporated and Natural Technology, Inc.
The dermal market is a multi-billion dollar market and presents an opportunity for Nerium to bring new dermal oleander-based products to market in the USA. Nerium hopes to develop a line of oleander-based dermal products for sun-damaged skin, several specific skin diseases, and skin cancer. In April 2008 Nerium Biotechnology, Inc. signed formulation and manufacturing agreements with Affiliated Consultants (formulation) and Natural Technology, Inc. (manufacturing). These negotiations included an additional new oleander extraction process which provides the opportunity for Nerium to obtain additional intellectual property.
April 2008
Presentation at the Annual Meeting of the American Association for Cancer Research, Dr. Robert A. Newman, M. D. Anderson Cancer Center
(Note: Poster Presentation on pending publication submitted to: Molecular Cancer Therapies in March 2008.)
AMERICAN ASSOCIATION FOR CANCER RESEARCH (AARC)
ANNUAL MEETING 2008
April 12-16, 2008
Dr. Robert A. Newman
The University of Texas MD Anderson Cancer Center
Pharmaceutical Development Center
Abstract Poster Presentation:
OLENADRIN-MEDIATED INHIBITION OF HUMAN TUMOR CELL PROLIFERATION: IMPORTANCE OF Na, K-ATPase a SUBUNITS AS DRUG TARGETS:
Dr. Robert A. Newman presented at the American Association for Cancer Research (AARC) annual meeting April 12-16, 2008 which this year was held in San Diego, California. More than 17,000 participants from 60 countries gathered to discuss an estimated 6,000 abstracts and to hear more than 500 invited presentations on new and significant discoveries in basic, clinical, and translational cancer research. Scientific award lectures, grant writing workshops, networking events, and educational sessions rounded out the comprehensive program.
(Click here to see presentation poster)
February 2008
Publication, Cardiac Glycoside Review published
(Dr. Robert A. Newman, M. D. Anderson Cancer Center and Dr. Keith I. Block, Block Medical Center)
Newman, R.A., et al. Cardiac Glycosides as Novel Cancer Therapeutic Agents. (An invited review); Molecular Interventions, 6(1) 2008.
December 2007
Publication on Autophagy published
(Dr. Robert A. Newman - M. D. Anderson Cancer Center)
Kondo, Y.; Newman, R.A., et al. Autophagic Cell Death of Human Pancreatic Tumor Cells Mediated by Oleandrin, a Lipid-Soluble Cardiac Glycoside; Integrative Cancer Therapies, 6(4); 2007.
November 2007
Consulting agreement signed with Quintiles Transnational Corporation
November 2007, Nerium Biotechnology, Inc. has signed a consulting agreement with Quintiles Transnational Corp. to pursue development and approval of oleander-based products in the United States. Quintiles, a global leader in pharmaceutical, biotechnology, and medical device product development as well as marketing-related services, has helped develop or commercialize many of the world’s best-selling drugs. With Quintiles assistance, Nerium plans to continue research, gather additional clinical data, and continue with new product development.
Go back
